{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:57:56Z","timestamp":1785560276750,"version":"3.56.0"},"reference-count":49,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2026,7,31]]},"DOI":"10.1536\/ihj.25-386","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:10:49Z","timestamp":1785449449000},"page":"381-395","source":"Crossref","is-referenced-by-count":0,"title":["Empagliflozin Attenuates Ferroptosis in Acute Myocardial Infarction via the AMPK\/NRF2\/SLC7A11 Signaling Pathway"],"prefix":"10.1536","volume":"67","author":[{"given":"Xiangrui","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Cardiology, 3201 Hospital of Xi&apos;an Jiaotong University Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Catheter Room, The Affiliated Hospital of Yan&apos;an University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Baoji Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lindahl B, Mills NL. A new clinical classification of acute myocardial infarction. Nat Med 2023; 29: 2200-5.","DOI":"10.1038\/s41591-023-02513-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Algoet M, Janssens S, Himmelreich U, <i>et al<\/i>. Myocardial ischemia-reperfusion injury and the influence of inflammation. Trends Cardiovasc Med 2023; 33: 357-66.","DOI":"10.1016\/j.tcm.2022.02.005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yoshimura C, Nagasaka A, Kurose H, Nakaya M. Efferocytosis during myocardial infarction. J Biochem 2020; 168: 1-6.","DOI":"10.1093\/jb\/mvaa051"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Del Buono MG, Moroni F, Montone RA, Azzalini L, Sanna T, Abbate A. Ischemic Cardiomyopathy and Heart Failure After Acute Myocardial Infarction. Curr Cardiol Rep 2022; 24: 1505-15.","DOI":"10.1007\/s11886-022-01766-6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Welt FGP, Batchelor W, Spears JR, <i>et al<\/i>. Reperfusion Injury in Patients With Acute Myocardial Infarction: JACC Scientific Statement. J Am Coll Cardiol 2024; 83: 2196-213.","DOI":"10.1016\/j.jacc.2024.02.056"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res 2021; 31: 107-25.","DOI":"10.1038\/s41422-020-00441-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C. Lipid Peroxidation and Iron Metabolism: Two Corner Stones in the Homeostasis Control of Ferroptosis. Int J Mol Sci 2022; 24: 449.","DOI":"10.3390\/ijms24010449"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wu X, Li J, Cheng H, Wang L. Ferroptosis and Lipid Metabolism in Acute Myocardial Infarction. Rev Cardiovasc Med 2024; 25: 149.","DOI":"10.31083\/j.rcm2505149"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Scarpellini C, Klejborowska G, Lanthier C, Hassannia B, Vanden Berghe T, Augustyns K. Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors. Trends Pharmacol Sci 2023; 44: 902-16.","DOI":"10.1016\/j.tips.2023.08.012"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rao S. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Adv Ther 2022; 39: 845-61.","DOI":"10.1007\/s12325-021-01989-z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev 2021; 26: 623-42.","DOI":"10.1007\/s10741-020-10038-w"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hernandez AF, Udell JA, Jones WS, <i>et al<\/i>. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation 2024; 149: 1627-38.","DOI":"10.1161\/CIRCULATIONAHA.124.069217"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Zhao M, Li N, Zhou H. SGLT1: A Potential Drug Target for Cardiovascular Disease. Drug Des Devel Ther 2023; 17: 2011-23.","DOI":"10.2147\/DDDT.S418321"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yang W, Li X, He L, <i>et al<\/i>. Empagliflozin improves renal ischemia-reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK-OPA1 pathway promotion. Cell Mol Biol Lett 2023; 28: 42.","DOI":"10.1186\/s11658-023-00457-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wang X, Chen X, Zhou W, <i>et al<\/i>. Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK\/NRF2 pathways. Acta Pharm Sin B 2022; 12: 708-22.","DOI":"10.1016\/j.apsb.2021.10.005"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Yao D, Bao L, Wang S, <i>et al<\/i>. Isoliquiritigenin alleviates myocardial ischemia-reperfusion injury by regulating the Nrf2\/HO-1\/SLC7a11\/GPX4 axis in mice. Free Radic Biol Med 2024; 221: 1-12.","DOI":"10.1016\/j.freeradbiomed.2024.05.012"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ma Y, Fei S, Chen X, <i>et al<\/i>. Chemerin attenuates acute kidney injury by inhibiting ferroptosis via the AMPK\/NRF2\/SLC7A11 axis. Commun Biol 2024; 7: 1679.","DOI":"10.1038\/s42003-024-07377-x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yu Q, Zhang N, Gan X, <i>et al<\/i>. EGCG attenuated acute myocardial infarction by inhibiting ferroptosis via miR-450b-5p\/ACSL4 axis. Phytomedicine 2023; 119: 154999.","DOI":"10.1016\/j.phymed.2023.154999"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Wang Z, Yao M, Jiang L, <i>et al<\/i>. Dexmedetomidine attenuates myocardial ischemia\/reperfusion-induced ferroptosis via AMPK\/GSK-3beta\/Nrf2 axis. Biomed Pharmacother 2022; 154: 113572.","DOI":"10.1016\/j.biopha.2022.113572"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Pietrafesa G, De Zio R, Scorza SI, <i>et al<\/i>. Targeting unfolded protein response reverts ER stress and ER Ca (2+) homeostasis in cardiomyocytes expressing the pathogenic variant of Lamin A\/C R321X. J Transl Med 2023; 21: 340.","DOI":"10.1186\/s12967-023-04170-y"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Miao W, Hu YZ. Aldo-Keto reductase 1C3 reduces myocardial cell damage after acute myocardial infarction by activating the Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2-antioxidant response element pathway to inhibit ferroptosis. J Geriatr Cardiol 2024; 21: 899-912.","DOI":"10.26599\/1671-5411.2024.09.001"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Lu Q, Yang L, Xiao JJ, <i>et al<\/i>. Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK\/NRF2 pathway. Free Radic Biol Med 2023; 195: 89-102.","DOI":"10.1016\/j.freeradbiomed.2022.12.088"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Wang CC, Li Y, Qian XQ, <i>et al<\/i>. Empagliflozin alleviates myocardial I\/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK\/ATF4\/Beclin1 pathway. J Drug Target 2022; 30: 858-72.","DOI":"10.1080\/1061186X.2022.2064479"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Li X, Ma N, Xu J, <i>et al<\/i>. Targeting Ferroptosis: Pathological Mechanism and Treatment of Ischemia-Reperfusion Injury. Oxid Med Cell Longev 2021; 2021: 1587922.","DOI":"10.1155\/2021\/1587922"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Min J, Wu L, Liu Y, <i>et al<\/i>. Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. Life Sci 2023; 312: 121207.","DOI":"10.1016\/j.lfs.2022.121207"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Liu CH, Ho YC, Lee WC, <i>et al<\/i>. Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin Attenuates Sorafenib-Induced Myocardial Inflammation and Toxicity. Environ Toxicol 2024; 39: 4844-58.","DOI":"10.1002\/tox.24362"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Xiang Q, Yi X, Zhu XH, Wei X, Jiang DS. Regulated cell death in myocardial ischemia-reperfusion injury. Trends Endocrinol Metab 2024; 35: 219-34.","DOI":"10.1016\/j.tem.2023.10.010"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Zhang H, Pan J, Huang S, <i>et al<\/i>. Hydrogen sulfide protects cardiomyocytes from doxorubicin-induced ferroptosis through the SLC7A11\/GSH\/GPx4 pathway by Keap1 S-sulfhydration and Nrf2 activation. Redox Biol 2024; 70: 103066.","DOI":"10.1016\/j.redox.2024.103066"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Zhang W, Lu J, Wang Y, <i>et al<\/i>. Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes by Inhibiting Inflammation and Ferroptosis through Activating AMPK Pathway. Int J Mol Sci 2023; 24: 858.","DOI":"10.3390\/ijms24010858"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Wani A, Al Rihani SB, Sharma A, <i>et al<\/i>. Crocetin promotes clearance of amyloid-beta by inducing autophagy via the STK11\/LKB1-mediated AMPK pathway. Autophagy 2021; 17: 3813-32.","DOI":"10.1080\/15548627.2021.1872187"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Wang Y, Ding Y, Sun P, <i>et al<\/i>. Empagliflozin-Enhanced Antioxidant Defense Attenuates Lipotoxicity and Protects Hepatocytes by Promoting FoxO3a- and Nrf2-Mediated Nuclear Translocation via the CAMKK2\/AMPK Pathway. Antioxidants (Basel) 2022; 11: 799.","DOI":"10.3390\/antiox11050799"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Chen S, Wang Q, Bakker D, <i>et al<\/i>. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2. Basic Res Cardiol 2024; 119: 751-72.","DOI":"10.1007\/s00395-024-01067-9"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Cai W, Chong K, Huang Y, Huang C, Yin L. Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress. Redox Biol 2024; 69: 103010.","DOI":"10.1016\/j.redox.2023.103010"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Baartscheer A, Schumacher CA, Wust RC, <i>et al<\/i>. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits. Diabetologia 2017; 60: 568-73.","DOI":"10.1007\/s00125-016-4134-x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Alsereidi FR, Khashim Z, Marzook H, <i>et al<\/i>. Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived beta cells. Cardiovasc Diabetol 2024; 23: 388.","DOI":"10.1186\/s12933-024-02481-y"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Liu X, Qiu Y, Huang N, <i>et al<\/i>. Citronellal alleviates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and apoptosis via Na(+)\/H(+) exchanger-1 inhibition. J Biochem Mol Toxicol 2022; 36: e22971.","DOI":"10.1002\/jbt.22971"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Chen GH, Song CC, Pantopoulos K, Wei XL, Zheng H, Luo Z. Mitochondrial oxidative stress mediated Fe-induced ferroptosis via the NRF2-ARE pathway. Free Radic Biol Med 2022; 180: 95-107.","DOI":"10.1016\/j.freeradbiomed.2022.01.012"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Quagliariello V, De Laurentiis M, Rea D, <i>et al<\/i>. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol 2021; 20: 150.","DOI":"10.1186\/s12933-021-01346-y"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Chen D, Shi J, Wu Y, <i>et al<\/i>. Dapagliflozin alleviates high-fat-induced obesity cardiomyopathy by inhibiting ferroptosis. ESC Heart Fail 2025; 12: 1358-73.","DOI":"10.1002\/ehf2.15150"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Quagliariello V, Canale ML, Bisceglia I, <i>et al<\/i>. Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-kappaB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity. Front Cardiovasc Med 2024; 11: 1289663.","DOI":"10.3389\/fcvm.2024.1289663"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Packer M, Anker SD, Butler J, <i>et al<\/i>. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383: 1413-24.","DOI":"10.1056\/NEJMoa2022190"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Schwegel N, Strohhofer C, Kolesnik E, <i>et al<\/i>. Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial. Clin Res Cardiol 2025; 114: 629-39.","DOI":"10.1007\/s00392-024-02523-1"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Erlinge D, James S, Deanfield J, <i>et al<\/i>. Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. ESC Heart Fail 2025; 12: 4184-93.","DOI":"10.1002\/ehf2.15420"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Ci Mee X, Kheng Lim G, Ibrahim R, <i>et al<\/i>. SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis. Eur Heart J Cardiovasc Pharmacother 2025; 11: 334-42.","DOI":"10.1093\/ehjcvp\/pvaf026"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Badreldin H, Elshal M, El-Karef A, Ibrahim T. Empagliflozin protects the heart from atrial fibrillation in rats through inhibiting the NF-kappaB\/HIF-1alpha regulatory axis and atrial remodeling. Int Immunopharmacol 2024; 143: 113403.","DOI":"10.1016\/j.intimp.2024.113403"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Zou R, Shi W, Qiu J, <i>et al<\/i>. Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion injury through improving mitochondrial homeostasis. Cardiovasc Diabetol 2022; 21: 106.","DOI":"10.1186\/s12933-022-01532-6"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Petsouki E, Ender S, Sosa Cabrera SN, Heiss EH. AMPK-Mediated Phosphorylation of Nrf2 at S374\/S408\/S433 Favors Its betaTrCP2-Mediated Degradation in KEAP1-Deficient Cells. Antioxidants (Basel) 2023; 12: 1586.","DOI":"10.3390\/antiox12081586"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Matzinger M, Fischhuber K, Poloske D, Mechtler K, Heiss EH. AMPK leads to phosphorylation of the transcription factor Nrf2, tuning transactivation of selected target genes. Redox Biol 2020; 29: 101393.","DOI":"10.1016\/j.redox.2019.101393"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Choi EJ, Oh HT, Lee SH, <i>et al<\/i>. Metabolic stress induces a double-positive feedback loop between AMPK and SQSTM1\/p62 conferring dual activation of AMPK and NFE2L2\/NRF2 to synergize antioxidant defense. Autophagy 2024; 20: 2490-510.","DOI":"10.1080\/15548627.2024.2374692"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/4\/67_25-386\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:14:16Z","timestamp":1785557656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/4\/67_25-386\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.25-386","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"25-386"}}